Skip to main content

Table 2 Baseline levels of coagulation markers

From: The effects of continuous venovenous hemofiltration on coagulation activation

Coagulation marker

Group A

Group B

P value

Normal range (reference value)

Prothrombin fragment F1+2 (nmol/l)

2.5 (0.9–3.8)

4.1 (2.3–6.6)

0.20

0.3–1.6

Soluble tissue factor (pg/ml)

126 (73–216)

207 (30–322)

0.59

55–256

Activated factor VII (mU/ml)

61 (14–141)

97 (20–267)

0.52

16–142

Tissue factor pathway inhibitor (ng/ml)

167 (104–192)

127 (56–200)

0.83

39–149

Antithrombin (%)

78 (46–100)

45 (16–81)

0.09

80–140

Protein C (%)

63 (29–164)

41 (16–89)

0.34

65–110

Plasmin–antiplasmin complexes (ng/ml)

682 (635–788)

727 (281–1287)

1.0

221–512

Tissue-type plasminogen activator (ng/ml)

14.3 (7.0–44.6)

11.7 (8.6–51.7)

0.75

1.5–15

Plasminogen activator inhibitor type 1 (ng/ml)

135 (16–275)

526 (129–2191)

0.06

10–70

Kallikrein–C1-inhibitor complex (mU/ml)

8.2 (5.1–9.9)

11.1 (8.5–18.5)

0.02

<0.6

Activated factor XII–C1-inhibitor complex (mU/ml)

1.6 (1.3–1.8)

2.4 (1.8–4.4)

0.02

<0.5

Platelet count (× 109/l)

136 (90–329)

63 (30–101)

0.02

150–350

Prothrombin time (s)

13.5 (12.7–16.9)

17.5 (15.2–26.1)

0.05

10–13

Activated partial thromboplastin time (s)

25 (21–29)

37 (27–57)

0.02

21–27

  1. Group A, patients with increased thrombin generation; group B, patients without increased thrombin generation. Data presented as median (range).